Global Oncology Biosimilars Treatment Market Trends, Analysis, Growth, and Forecast: 2018 to 2027

MarketResearch.biz delivers in-depth insights on the global oncology biosimilars treatment market in its upcoming report titled, “Global Oncology Biosimilars Treatment Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The global oncology biosimilars treatment market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global oncology biosimilars treatment market report has been segmented on the basis of product type, cancer type, distribution channel, and region.

Request Covid - 19 Impact

Biosimilar are similar to biological medicine which contains active substance from a biological source such as organisms or living cells. They are large, complex structure, possesses potential structural variations and requires large number of clinical trials. It is also referred as biogenerics. It is biotherapeutic product which is similar in term of safety, quality and efficacy to the reference biotherapeutic products. Many biologics are also produced using recombinant DNA technology.

Increasing number of cancer cases globally is expected to drive the global oncology biosimilars treatment market over the forecast period. In addition, increasing number of biosimilar approval by health authorities for treatment of cancer is further expected to propel the market growth over the forecast period. Moreover, biosimilar is expected to gain popularity owing to its lower cost as compared to biologics which in turn is expected to drive the growth of global oncology biosimilars treatment market over the forecast period.

However, manufacturing companies have to launch the product after patent expiration of reference biologic which is expected to limit the market growth. In addition, high manufacturing cost and time required for development of oncology biosimilar is expected to restrain the market growth over the forecast period.

North America market dominates the global oncology biosimilars treatment market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to the increasing incidence of cancer, developed healthcare infrastructure, favorable government initiatives, and increasing number of approvals in the region. Europe accounts for second-largest revenue share contribution to the global oncology biosimilars treatment market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively. The market in the Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years. This is attributed to improving healthcare infrastructure, growing number of contract manufacturing organization and increasing incidence of cancer in the region.

Global oncology biosimilars treatment market segmentation, by product type:

• Monoclonal antibody
• Immunomodulators
• Others

Global oncology biosimilars treatment market segmentation, by cancer type:

• Blood Cancer
• Breast Cancer
• Lung Cancer
• Cervical Cancer
• Colorectal cancer
• Kidney cancer
• Others

Global oncology biosimilars treatment market segmentation, by distribution channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Global oncology biosimilars treatment market segmentation, by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Amgen Inc.
• Allergan, Plc
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Novartis AG
• Biocon Limited.
• Celltrion Healthcare
• Biogen Inc.
• F Hoffmann-La Roche